Fresenius Kabi Issues voluntary nationwide recall of two lots of fluorouracil injection
Fresenius Kabi USA, LLC has announced a voluntary recall of two lots of Fluorouracil Injection, USP 5g/100mL (50mg/mL), 100mL fill in 100mL vials, to the user level due to the potential for glass particulate. Fluorouracil is a chemotherapy drug that is administered intravenously and indicated for the treatment of a variety of cancers.
Products containing glass particulate should not be administered intravenously due to the potential for life-threatening consequences. Reports in the literature suggest that sequelae of thromboembolism, such as pulmonary emboli, phlebitis, granulomas, or fibrosis may occur. The affected lots, distributed between December 6, 2018 and February 20, 2019, are listed here.
The company is issuing this notification after finding glass particulate in five vials in retained sample inventory of lot 6120341 during an inspection for a quality investigation. The second lot (6120420) is included in the recall as a precautionary measure as it was produced in the same filling campaign. To date, Fresenius Kabi has not received any complaints or reports of adverse events related to this recall.
Fresenius Kabi is notifying its distributors and customers by letter and asking customers and distributors to check their stock immediately and to quarantine and discontinue the use and distribution of any affected product. Distributors should notify their customers and direct them to quarantine and discontinue distributing or dispensing any affected lots, and to return the product to Fresenius Kabi.
